Also from this source

You just read:

Cerulean Announces First Patient Dosed in Phase 1b/2a Study of CRLX101 in Combination with Avastin® in Renal Cancer

News provided by

Cerulean Pharma Inc.

Jul 02, 2012, 09:00 ET